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endometriosis
hormone therapyCutaneous endometriosis is a disorder that primarily affects women of reproductive age. The disorder is
most commonly associated with cyclical pain during menses, but it can be difficult to diagnose in the
absence of these symptoms and requires biopsy testing for a definitive diagnosis. We report on a case
of a 41-year-old patient undergoing hormonal therapy for infertility who presented with a painful firm
subcutaneous nodule in the umbilicus. She was ultimately diagnosed with cutaneous endometriosis
and underwent surgical excision. In this report, we discuss the differential diagnosis and comment on
treatment options, including surgical excision with wide margins or treatment with hormonal agents,
such as danazol or leuprolide. Finally, we discuss whether patients with cutaneous endometriosis should
receive an additional evaluation for pelvic endometriosis.
 2019 Published by Elsevier Inc. on behalf of Women’s Dermatologic Society. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Endometriosis represents the presence of non-neoplastic
endometrial tissue outside the uterus. The disease is relatively
common and typically affects the ovaries and presents with deep
pelvic pain, dyspareunia, and dysmenorrhea. Cutaneous
endometriosis is relatively uncommon and occurs when endome-
trial glands and stroma reside in the skin. Cutaneous endometriosis
can be divided into primary and secondary endometriosis. The
pathogenesis for primary cutaneous endometriosis remains
unclear, but secondary cutaneous endometriosis is believed to
occur due to seeding after abdominal or pelvic surgery.
Because the condition is rare and can mimic presentations of
other diseases, such as keloid or dermatofibroma, cutaneous
endometriosis can be difficult to diagnose. Punch biopsy can be
performed to obtain tissue for histopathologic testing, but physi-
cians must take care to obtain abdominal ultrasound if there is
potential for uterocutaneous fistula. Once the diagnosis has been
established, treatment options include hormonal agents and surgi-
cal excision with wide margins.Case report
A 41-year-old woman presented to our department with a
5-month history of a painful firm subcutaneous nodule in the
umbilicus. She experienced flares of pain with her menstrual cycle.
Her medical history was notable for a missed abortion, for which
she underwent dilation and curettage in 2009. She also underwent
laparoscopic left salpingectomy for a ruptured ectopic pregnancy
in 2013. At the time of presentation, the patient was undergoing
fertility treatments, including subcutaneous injections of fol-
litropin beta and choriogonadotropin alfa.
On physical examination, a firm subcutaneous nodule was
noted on the umbilicus with slight erythema of the overlying skin.
A diagnosis of cutaneous endometriosis was suspected given the
patient’s history of laparoscopic salpingectomy and flares of pain
with menstrual periods. An ultrasound was performed with repro-
ductive endocrinology to rule out fistula. Once completed, a punch
biopsy of the nodule was performed (Figs. 1 and 2). The biopsy
results showed endometrial glands with encompassing fibrotic
stroma, consistent with cutaneous endometriosis. The site was
most likely seeded during the laparoscopic port site entry during
her left salpingectomy in 2013.
The patient was counseled with regard to the etiology of the
disease and given treatment options of hormonal therapy with
danazol or leuprolide versus surgical excision. Because the patient
was undergoing fertility treatment at the time, she declined hor-
monal therapy. Her obstetrics and gynecology team was informed,
Fig. 1. Endometrial glands surrounded by scant hypercellular stroma (right),
consistent with a diagnosis of endometriosis. The remainder of the tissue is fibrotic
and represents a chronic reactive change induced by the adjacent cycling ectopic
tissue.
Fig. 2. Endometrial gland (left) with plump stromal cells and extravasated
erythrocytes prominently flanking the gland. Hemorrhagic stroma in the skin
evokes secondary fibrosis, which explains the prominent hemorrhagic scarring to
the right of the frame.
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ment for excision of the nodule.
Discussion
Cutaneous endometriosis is a disorder that primarily affects
women of reproductive age and classically presents as a firm sub-
cutaneous papule or nodule that averages 2 cm in diameter (Loh
et al., 2017). Its color can range from blue or violaceous to brown
or skin-colored. Patients frequently experience cyclical pain, swel-
ling, and even bleeding that corresponds with their menstrual
cycle (Victory et al., 2007). A diagnosis of cutaneous endometriosis
can be made once the presence of endometrial glands and stroma
in the skin is established. Notably, an ultrasound should be com-
pleted prior to performing a punch biopsy of the lesion to rule
out the presence of uterocutaneous fistula.
The skin is an uncommon location for endometriosis, and cuta-
neous endometriosis cases comprise <1% of all cases in large series
(Victory et al., 2007). One review demonstrated that only 109 cases
of cutaneous endometriosis had been described in the literature up
to that point in time (Lopez-Soto et al., 2018). Cutaneous
endometriosis is subdivided into two categories depending on
patients’ surgical history. Primary cutaneous endometriosis refers
to cases in which the endometriosis develops spontaneously with-out any history of local surgery. It is the less common of the two
(only 30% of patients present without a surgical history that could
explain their cutaneous manifestations; Victory et al., 2007). Sec-
ondary cutaneous endometriosis, also called scar endometriosis,
is associated with prior abdominal or pelvic surgery (Loh et al.,
2017).
Our patient was diagnosed with cutaneous endometriosis based
on the cyclical nature of her pain and the diagnostic der-
matopathology. Identifying the patient’s surgical history was cru-
cial to subclassifying our patient’s involvement as most likely
being secondary in nature.
As with our patient, the most common location for both pri-
mary and secondary cutaneous endometriosis is the umbilicus.
Umbilical cutaneous endometriosis comprises 30% to 40% of all
cutaneous endometriosis cases, but other locations such as the
groin, arm, episiotomy wounds, appendectomy scars, and cesarean
scars have also been described (Victory et al., 2007).
Many theories have been proposed with regard to the patho-
genesis of primary and secondary cutaneous endometriosis.
Secondary cutaneous endometriosis is perhaps easier to conceptu-
alize, and the prevailing hypothesis remains that endometrial cells
dislodged during surgery seed the wound within and adjacent to
the incision sites. In cases of primary cutaneous endometriosis,
some postulate that seeding occurs hematogenously or via lym-
phatics (Victory et al., 2007). In cases of primary cutaneous
endometriosis of the umbilicus, some have postulated that the
pathogenesis is similar to that of secondary cutaneous endometrio-
sis, with the umbilicus acting as a physiologic scar. A third theory
(i.e., metaplastic theory) has offered an explanation for both pri-
mary and secondary cutaneous endometriosis and states that cuta-
neous endometriosis is the result of primitive pluripotent
mesenchymal cells undergoing specialized differentiation and
metaplasia into endometrial tissue.
The differential diagnosis of umbilical lesions with similar pre-
sentation includes keloid, dermatofibroma, dermatofibrosarcoma
protuberans, and cutaneous metastasis of cancer (e.g., Sister Mary
Joseph nodule). Distinguishing between these lesions can be chal-
lenging, particularly when patients do not endorse a history of
cyclical pain that corresponds with menses.
Adult patients with a keloid typically present with a history of
keloid or hypertrophic scars elsewhere on the body. Keloids appear
as well-circumscribed pink-to-purple, firm, smooth nodules or pla-
ques with regular or irregular borders. These can develop at umbil-
ical surgical scars, but keloids favor locations with increased
tension, such as the shoulder or arms. Sometimes, patients with
cutaneous endometriosis will present having already received
intralesional corticosteroids for a misdiagnosis of keloid scar (Loh
et al., 2017). Intralesional corticosteroids are ineffective to treat
cutaneous endometriosis.
Dermatofibromas are benign fibrohistiocytic tumors that pre-
sent as asymptomatic firm masses that dimple when compressed
laterally due to tethering of the epidermis to the underlying nodule
(i.e., dimple sign). Dimpling is not considered specific to dermatofi-
bromas but has not been described in cutaneous endometriosis in
the literature.
Cutaneous endometriosis can also mimic malignancy. Der-
matofibrosarcoma protuberans, a locally aggressive but low-
grade soft tissue sarcoma, classically presents in early stages as
an asymptomatic, indurated plaque that slowly enlarges. In later
stages, the tumor can become raised, firm, and nodular, and telang-
iectasia may be noted in the surrounding skin. The presence of
nodules signifies that the growth has become accelerated, and
often nodular growth is associated with ulceration or bleeding,
which does not classically occur in cutaneous endometriosis. Ulti-
mately, this condition can only be definitively differentiated from
cutaneous endometriosis by biopsy.
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from the umbilicus and represents malignant, metastatic cancer,
typically presents with pain, change in bowel habits, or anemia
due to underlying abdominal or pelvic cancer. Because gastroin-
testinal malignancy, particularly that of the ascending colon, can
initially have an occult presentation, this diagnosis should be con-
sidered even in the absence of obstructive symptoms.
Once a diagnosis of either primary or secondary cutaneous
endometriosis is established, the definitive treatment is surgical
excision with wide margins, which was the treatment option
selected by the patient in this case. The prognosis of cutaneous
endometriosis is generally considered favorable. Lopez-Soto et al.
(2018) studied 33 women with cutaneous endometriosis; 31 of
the women had a surgical history that suggested secondary cuta-
neous endometriosis. The majority of these women (90%) received
surgical excision. Overall, cutaneous endometriosis recurred in 3
women (9%), suggesting surgical excision is a reasonable manage-
ment option.
The perioperative management of patients may vary. Some sug-
gest performing surgery at the end of the menstrual cycle when
lesions are as small as possible, but there is no data to support this
practice. Others have recommended either preoperative or postop-
erative hormonal agents. Preoperatively, the goal of hormonal
therapy is to address patients’ discomfort and shrink lesions to a
smaller size to facilitate complete removal during surgery. Postop-
eratively, the goal is to prevent recurrence. Currently, available
data do not comment on the best practices for the perioperative
management of cutaneous endometriosis.
Another option for patients who do not wish to undergo surgery
is treatment with hormonal agents alone, such as gonadotropin-
releasing hormone agonists or danazol. These agents work by pre-
venting cyclical proliferation of the endometrial tissue. The pri-
mary drawback to medical therapy is the potential for
recurrence; ectopic endometrial tissue may resume proliferation
once medications are discontinued (Loh et al., 2017). In one case
series, Drs. Robert Purvis and Steven Tyring (1994) describe two
cases in which medical management was attempted, one with
danazol and the other with leuprolide. In both cases, hormonal
therapy was able to relieve associated pain, and in one case the
nodule diminished in size by approximately 50%. However, the
patient treated with monthly injections of subcutaneous leuprolide
experienced return of her pain between her second and third treat-
ment cycles. Both patients opted for surgical excision of their
lesions within 1 year due to the unfavorable side effects of the hor-
monal therapies (Purvis and Tyring, 1994). Although surgical exci-
sion with wide margins is the gold standard for therapy, if the
decision is made to opt for hormonal therapy, surveillance withhistopathology should be considered due to case reports noting
instances of malignant transformation (Cameron et al., 2017).
The final question for those treating patients with cutaneous
endometriosis is whether there is an association between cuta-
neous and pelvic endometriosis that warrants gynecologic
workup for patients presenting with cutaneous disease. Vellido-
Cotelo et al. (2015) performed a retrospective case study in which
they examined the medical records of 17 patients with scar
endometriosis and found that only two (14%) had associated pel-
vic endometriosis. Although the number of patients studied was
quite low, the study authors stated that this 14% fell within the
8% to 15% range that represents the overall incidence of pelvic
endometriosis in the general population. Ultimately, patients
should be referred to the obstetrics and gynecology department
if they describe classic symptoms, including pain with menses,
dyspareunia, and infertility, and wish to explore diagnostic and
therapeutic options.
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